Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis

Long-term efficacy of CDK4/6 inhibitors in early HR+, HER2- high-risk breast cancer: An updated systematic review and meta-analysis

BackgroundThe confirmed efficacy of combining CDK4/6 inhibitors with endocrine therapy (ET) in HR+, HER2− early breast cancer patients in longer follow-up necessitates further investigation. This meta-analysis aims to comprehensively assess the impact of follow-up duration on the therapeutic activit...

Full description

Saved in:
Bibliographic Details
Main Authors: Ying Liu, Jun Su, Ping Wu, Wenjie Lv
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Subjects:
CDK4/6 inhibitor
early breast cancer
meta-analysis
follow-up duration
iDFS
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1564437/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items